{"id":"NCT00395694","sponsor":"GlaxoSmithKline","briefTitle":"Clinical Evaluation of BW430C in Epilepsy","officialTitle":"Clinical Evaluation of BW430C in Epilepsy<Phase III Study>","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08-07","primaryCompletion":"2009-03-01","completion":"2009-03-26","firstPosted":"2006-11-03","resultsPosted":"2012-09-17","lastUpdate":"2018-09-26"},"enrollment":102,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"lamictal","otherNames":[]}],"arms":[{"label":"lamictal","type":"EXPERIMENTAL"}],"summary":"To evaluate safety information of BW430C when administered using the lower starting doses and slower dose escalations as recommended Global Data Sheet","primaryOutcome":{"measure":"Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment","timeFrame":"8 weeks","effectByArm":[{"arm":"Adults: LTG","deltaMin":2,"sd":null},{"arm":"Adolescents: LTG","deltaMin":3,"sd":null},{"arm":"Total: LTG","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG002","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Somnolence","Diarrhoea","Pyrexia"]}}